APGE
Apogee Therapeutics, Inc.
Biotechnology
Market Cap$5.60B
5Y Perf.+282.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
APGE vs ACLX
Revenue, margins, valuation, and 5-year total return — side by side.
ACLX
Arcellx, Inc.
Biotechnology
Market Cap$6.73B
5Y Perf.+235.2%
APGE vs ACLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | APGE | ACLX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $5.60B | $6.73B |
| Revenue (TTM) | $0.00 | $22M |
| Net Income (TTM) | $0.00 | $-229M |
| Gross Margin | — | -64.8% |
| Operating Margin | — | -11.4% |
| Total Debt | $9M | $96M |
| Cash & Equiv. | $132M | $80M |
APGE vs ACLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
APGE
ACLX
| Stock | Jul 23 | May 26 | Return |
|---|---|---|---|
| Apogee Therapeutics… (APGE) | 100 | 382.3 | +282.3% |
| Arcellx, Inc. (ACLX) | 100 | 335.2 | +235.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: APGE vs ACLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: APGE leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
APGE
Apogee Therapeutics, Inc.
The Growth Play
APGE carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth -27.9%
- Lower volatility, beta 1.33, Low D/E 1.0%, current ratio 26.57x
- Beta 1.33, current ratio 26.57x
Best for: growth exposure and sleep-well-at-night
ACLX
Arcellx, Inc.
The Long-Run Compounder
ACLX is the clearest fit if your priority is long-term compounding.
- 5.8% 10Y total return vs APGE's 285.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | APGE | 100.8% revenue growth vs ACLX's -79.4% |
| Quality / Margins | APGE | 3.2% margin vs ACLX's -10.3% |
| Stability / Safety | APGE | Lower D/E ratio (1.0% vs 23.9%) |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | APGE | +132.2% vs ACLX's +117.4% |
| Efficiency (ROA) | APGE | -30.3% ROA vs ACLX's -36.2%, ROIC -31.3% vs -46.2% |
APGE vs ACLX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAPGELAGGINGACLX
ACLXArcellx, Inc.
1leads
APGEApogee Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs ACLXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
APGE1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
APGE8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
ACLX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
APGE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACLX and APGE operate at a comparable scale, with $22M and $0 in trailing revenue.
| Metric | APGEApogee Therapeuti… | ACLXArcellx, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $22M |
| EBITDAEarnings before interest/tax | -$284M | -$246M |
| Net IncomeAfter-tax profit | $0 | -$229M |
| Free Cash FlowCash after capex | -$233M | -$213M |
| Gross MarginGross profit ÷ Revenue | — | -64.8% |
| Operating MarginEBIT ÷ Revenue | — | -11.4% |
| Net MarginNet income ÷ Revenue | — | -10.3% |
| FCF MarginFCF ÷ Revenue | — | -9.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -89.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.6% | -13.6% |
APGE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — APGE and ACLX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | APGEApogee Therapeuti… | ACLXArcellx, Inc. |
|---|---|---|
| Market CapShares × price | $5.6B | $6.7B |
| Enterprise ValueMkt cap + debt − cash | $5.5B | $6.7B |
| Trailing P/EPrice ÷ TTM EPS | -19.39x | -28.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 302.09x |
| Price / BookPrice ÷ Book value/share | 5.49x | 16.10x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — APGE and ACLX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
APGE leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
APGE delivers a -31.6% return on equity — every $100 of shareholder capital generates $-32 in annual profit, vs $-55 for ACLX. APGE carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACLX's 0.24x. On the Piotroski fundamental quality scale (0–9), APGE scores 4/9 vs ACLX's 1/9, reflecting mixed financial health.
| Metric | APGEApogee Therapeuti… | ACLXArcellx, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -31.6% | -55.4% |
| ROA (TTM)Return on assets | -30.3% | -36.2% |
| ROICReturn on invested capital | -31.3% | -46.2% |
| ROCEReturn on capital employed | -34.9% | -46.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.01x | 0.24x |
| Net DebtTotal debt minus cash | -$123M | $16M |
| Cash & Equiv.Liquid assets | $132M | $80M |
| Total DebtShort + long-term debt | $9M | $96M |
| Interest CoverageEBIT ÷ Interest expense | — | -8.45x |
APGE leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — APGE and ACLX each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACLX five years ago would be worth $68,494 today (with dividends reinvested), compared to $38,535 for APGE. Over the past 12 months, APGE leads with a +132.2% total return vs ACLX's +117.4%. The 3-year compound annual growth rate (CAGR) favors APGE at 56.8% vs ACLX's 38.6% — a key indicator of consistent wealth creation.
| Metric | APGEApogee Therapeuti… | ACLXArcellx, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +8.0% | +81.7% |
| 1-Year ReturnPast 12 months | +132.2% | +117.4% |
| 3-Year ReturnCumulative with dividends | +285.4% | +166.2% |
| 5-Year ReturnCumulative with dividends | +285.4% | +584.9% |
| 10-Year ReturnCumulative with dividends | +285.4% | +584.9% |
| CAGR (3Y)Annualised 3-year return | +56.8% | +38.6% |
Evenly matched — APGE and ACLX each lead in 3 of 6 comparable metrics.
Risk & Volatility
ACLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACLX is the less volatile stock with a -0.34 beta — it tends to amplify market swings less than APGE's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACLX currently trades 99.9% from its 52-week high vs APGE's 85.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | APGEApogee Therapeuti… | ACLXArcellx, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.33x | -0.34x |
| 52-Week HighHighest price in past year | $95.31 | $115.13 |
| 52-Week LowLowest price in past year | $34.34 | $47.86 |
| % of 52W HighCurrent price vs 52-week peak | +85.8% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 79.9 |
| Avg Volume (50D)Average daily shares traded | 865K | 1.6M |
ACLX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates APGE as "Buy" and ACLX as "Hold". Consensus price targets imply 33.8% upside for APGE (target: $109) vs -2.3% for ACLX (target: $112).
| Metric | APGEApogee Therapeuti… | ACLXArcellx, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $109.44 | $112.45 |
| # AnalystsCovering analysts | 10 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
APGE leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ACLX leads in 1 (Risk & Volatility). 2 tied.
Best OverallApogee Therapeutics, Inc. (APGE)Leads 2 of 6 categories
Loading custom metrics...
APGE vs ACLX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is APGE or ACLX a better buy right now?
Analysts rate Apogee Therapeutics, Inc.
(APGE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — APGE or ACLX?
Over the past 5 years, Arcellx, Inc.
(ACLX) delivered a total return of +584. 9%, compared to +285. 4% for Apogee Therapeutics, Inc. (APGE). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus APGE's +285. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — APGE or ACLX?
By beta (market sensitivity over 5 years), Arcellx, Inc.
(ACLX) is the lower-risk stock at -0. 34β versus Apogee Therapeutics, Inc. 's 1. 33β — meaning APGE is approximately -495% more volatile than ACLX relative to the S&P 500. On balance sheet safety, Apogee Therapeutics, Inc. (APGE) carries a lower debt/equity ratio of 1% versus 24% for Arcellx, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — APGE or ACLX?
On earnings-per-share growth, the picture is similar: Apogee Therapeutics, Inc.
grew EPS -27. 9% year-over-year, compared to -103. 5% for Arcellx, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — APGE or ACLX?
Apogee Therapeutics, Inc.
(APGE) is the more profitable company, earning 0. 0% net margin versus -1027. 3% for Arcellx, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: APGE leads at 0. 0% versus -1135. 6% for ACLX. At the gross margin level — before operating expenses — ACLX leads at 70. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — APGE or ACLX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is APGE or ACLX better for a retirement portfolio?
For long-horizon retirement investors, Arcellx, Inc.
(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 34), +584. 9% 10Y return). Both have compounded well over 10 years (ACLX: +584. 9%, APGE: +285. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between APGE and ACLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.